Quantinno Capital Management
AVBP icon

Quantinno Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Quantinno Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.48M Buy
48,743
+12,092
+33% +$370K ﹤0.01% 2464
2026
Q2 		$1.27M Buy
36,651
+5,655
+18% +$167K ﹤0.01% 2378
2026
Q1 		$715K Buy
+30,996
New +$700K ﹤0.01% 2439

Other funds holding AVBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HSG Holding
HSG Holding Na, Hong Kong $1.26B AUM 34.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
E Fund Management
E Fund Management Guangzhou, China $4.53B AUM
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Quantinno Capital Management's AVBP Position: Q3 2026 in Review

Quantinno Capital Management increased its ArriVent BioPharma (AVBP) stake by 33% in Q3 2026, buying an estimated $370K and bringing the position to 48,743 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2464.

Quantinno Capital Management first reported a position in AVBP in Q1 2026 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Quantinno Capital Management held 48,743 shares of ArriVent BioPharma worth $1.48M as of Q3 2026.
  • Quantinno Capital Management bought 12,092 ArriVent BioPharma shares in Q3 2026, an estimated $370K.
  • ArriVent BioPharma made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #2464 holding.
  • Quantinno Capital Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.